Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 67Genitourinary 16Gastrointestinal 15Gynecologic 13Thoracic 11Breast 10Sarcoma 7Head & Neck 6CNS 5Plasma cell 3Lymphoid 3Other hematologic neoplasm 1

Conditions

Multiple Myeloma 118Myelodysplastic Syndromes 37Hodgkin Disease 35Leukemia, Myeloid, Acute 33Lymphoma 31Lymphoma, Non-Hodgkin 30Neoplasms, Plasma Cell 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia 26Leukemia, Lymphocytic, Chronic, B-Cell 23Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Myeloproliferative Disorders 19Hematologic Neoplasms 18Primary Myelofibrosis 17Recurrence 12Anemia, Aplastic 12Lymphoma, Follicular 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Lymphoma, B-Cell, Marginal Zone 9Hematologic Diseases 9Burkitt Lymphoma 9Leukemia, Prolymphocytic 8Leukemia, Plasma Cell 8Leukemia, Myelomonocytic, Chronic 8Anemia, Refractory, with Excess of Blasts 6Polycythemia Vera 4Ovarian Neoplasms 4Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3

Interventions

fludarabine 3Cyclophosphamide 3Specimen Handling 2Magnetic Resonance Spectroscopy 2zimberelimab 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1sapanisertib 1resiquimod 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1marizomib 1larotrectinib 1ipatasertib 1interferon-alfa-1b 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1cobimetinib 1cc-486 1capivasertib 1binimetinib 1adavosertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × fludarabine × Plasma cell × Clear all
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03399448 2023-06-22

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

University of Pennsylvania

Phase 1 Terminated
3 enrolled
DermatologicPlasma cellSarcoma

Melanoma, Multiple Myeloma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Shenzhen Second People's Hospital

Phase 1 Unknown
36 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡